ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Prognostic parameters for local control and survival after radiotherapy of stabilized bone metastases.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative radiotherapy following surgical stabilization in patients with bone metastases is commonly recommended. The aim of the study was to validate existing prognostic scores and parameters for local control and survival in patients with bone metastases treated with surgical resection with or without radiotherapy.
methodsThis retrospective single-institution study analyzed consecutive patients with bone metastases undergoing resection and/or stabilization mostly due to pathologic or impending fractures (with or without spinal compression). Additive radiotherapy was considered the standard of care. Various fractionated radiotherapy regimens have been applied; equivalent dose in 2 Gy fractions (EQD2) has been calculated to enable comparison between fractionations. Prognostic factors influencing local progression-free survival (LPFS) and overall survival (OS) were evaluated.
resultsThe median follow-up was 9 months (range 1-121 months). A total of 142 patients were included. Most patients underwent surgery due to pathologic (n = 86, 60.6%) or impending fracture (n = 54, 38.0%), with or without spinal compression. Most common histologies were breast (n = 30, 21.1%) and lung cancer (n = 30, 21.1%); most common metastasis locations were spine (n = 58, 40.8%), lower (n = 56, 39.4%) and upper extremities (n = 23, 16.2%). Postoperative radiotherapy was performed in 89 patients (62.7%). Location in the spine and prior irradiation were identified as poor prognostic factors for LPFS. In patients with spine metastases, improved LPFS was demonstrated in those treated with postoperative radiotherapy (2 years LPFS 96.7% ± 3.3% vs. 23.4 ± 19.0%; p = 0.003). Postoperative radiotherapy did not improve LPFS in patients with bone metastases outside the spine (p = 0.960). Better OS rates were demonstrated in patients with good performance status (ECOG) and with moderate and good prognosis according to the Tokuhashi score.
conclusionOur real-life data revealed that a significant number of patients did not receive postoperative radiotherapy for various reasons. Established prognostic scores (Tokuhashi and ECOG score) correlate with patient survival, and their use should be encouraged to determine optimal patient treatment and to identify patients who may benefit from postoperative radiotherapy, due to their longer life expectancy. LPFS improved with postoperative radiotherapy in spinal bone metastases, but not in nonspinal metastases.
Indexed as
Identifiers
42223601What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.